Introduction
Mortality of dialysis patients is excessive; the registry in the United States (USRDS) reports an annual mortality of >20%. Cardiovascular disease largely contributes to the excess risk. Diabetic dialysis patients have a higher comorbidity and even poorer outcome as compared to non diabetic patients on dialysis [1] , which is reflected by a five year survival of only 35% [2] . Therefore, identification of unknown risk factors is an important task in order to develop novel interventional strategies.
Pregnancy-associated plasma protein A (PAPP-A) is a zincbinding metalloproteinase which cleaves insulin like growth factor binding proteins, mainly IGFBP-4 [3] thus increasing insulin like growth factor (IGFs) and so allowing their action. The protein was first described in plasma of pregnant women (1974) [4] . Its concentration markedly increases during pregnancy and is 100-fold elevated in the first trimester of pregnancy as compared to healthy non-pregnant women and men [5, 6] . PAPP-A is also used routinely for screening of chromosomal anomalies in the first trimester of pregnancy [7] . Studies in previous years clearly demonstrate its significance also outside pregnancy, mainly in coronary artery disease [5] and chronic kidney disease [6,8e10] . Similarly to other proteins, which appear and increase in pregnancy, PAPP-A is required for normal growth and prenatal development [11] , while its increased concentrations later in the life is connected with pathological states [5, 6, 12] .
In 2001, the presence of PAPP-A was shown for the first time in eroded and ruptured atherosclerotic plaques as well as increased levels in patients with acute coronary syndrome [5] . It was further shown that PAPP-A is a predictor of cardiovascular events among patients presenting with cardiac chest pain [13] .
Studies in patients with kidney diseases found a relationship of PAPP-A to renal function with highest levels in patients on dialysis [12] . The molecule demonstrated prognostic potential in long-term hemodialysis patients [8e10] and renal transplant recipients [14] . Its role in specific cardiac and vascular events is unknown and of major interest. Patients with CKD represent a high-risk population for cardiovascular events and the pattern and composition of adverse events is changing in advanced stages of CKD.
Hence, the aim of our study was to evaluate the relationship of PAPP-A with adverse clinical events, including sudden death, stroke, myocardial infarction and infectious deaths in a large cohort of patients with diabetes undergoing hemodialysis namely participants of the German Diabetes and Dialysis Study (4D study).
Material and methods

Study design and participants
The 4D study methodology has previously been reported in detail [15] . The 4D study was a prospective randomized controlled trial investigating atorvastatin in 1255 patients with type 2 diabetes mellitus, age 18e80 years, and on hemodialysis for less than 2 years. Between March 1998 and October 2002, patients were recruited in 178 dialysis centers in Germany. The study conformed with the principles outlined in the Declaration of Helsinki. It was approved by the medical ethical committee, and all patients gave their written informed consent before inclusion.
Data collection
Information on age, gender and smoking status was obtained through patient interviews. Comorbidities, including the presence of coronary artery disease (CAD) and congestive heart failure (CHF), as well as the duration of diabetes mellitus and dialysis treatment were reported by the patients' nephrologists. CAD was defined by a history of MI, coronary artery bypass grafting surgery, percutaneous coronary intervention, and the presence of CAD, as documented by angiography. CHF was defined according to the classification system of the New York Heart Association. Blood pressure was measured in sitting position. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared.
PAPP-A measurements
PAPP-A was measured in serum samples taken at baseline before randomization and stored at À80 C. Blood was sampled before the start of dialysis sessions and administration of heparin or other medication.
PAPP-A was assessed immunochemically with TRACE (Time Resolved Amplified Cryptate Emission) technology based on nonradiating energy transfer. The commercial kit for PAPP-A determination (BRAHMS GmbH, Thermo Fisher Scientific) contains two different monoclonal antibodies e one is conjugated with europium cryptate and the other one with the fluorescent agent XL 665. The antigen (PAPP-A) present in serum samples is sandwiched between two conjugates. The fluorescent signal measured during the formation of the antigeneantibody complex by the KRYPTOR analyzer is proportional to the antigen concentration. The results are expressed in mIU/L. The intra-assay and inter-assay coefficients of variation were 9.6% and 8.8%, respectively [16] .
Outcome assessment
The primary endpoint of the 4D study was defined as a composite of cardiac death, non-fatal myocardial infarction (MI) and stroke, whichever occurred first (combined cardiovascular events; CVE). Sudden cardiac death (SCD) was considered as: death verified by terminal rhythm disorders in an electrocardiogram; death observed by witnesses within 1 h after onset of cardiac symptoms; death confirmed by autopsy; unexpected death, presumably or possibly of cardiac origin and in the absence of a potassium level larger or equal to 7.5 mmol/L before start of the three most recent hemodialysis sessions. MI was diagnosed when at least two of three criteria were met: typical symptoms; elevated levels of cardiac enzymes; diagnostic changes in the electrocardiogram. Stroke was defined as a neurologic deficit lasting longer than 24 h. Computed tomographic or magnetic resonance imaging was available in all but 16 cases. The 4D study endpoints were centrally adjudicated by three members of the endpoint committee blinded to study treatment and according to pre-defined criteria.
For the present analysis, combined cardiovascular events (CVE), sudden death, MI, stroke, all-cause mortality and deaths due to infection were all chosen as separate outcome measures. The categorization of these events was based on the primary judgment of the endpoint committee during the 4D Study.
Statistical analysis
Continuous variables were expressed as mean with standard deviation or median with interquartile ranges, as appropriate. Categorical variables were expressed as percentages.
The study population was divided into quartiles according to the PAPP-A concentration at baseline: 13.4 mIU/L (quartile 1), 13.5e17.0 mIU/L (quartile 2), 17.1e20.9 mIU/L (quartile 3), >20.9 mIU/L (quartile 4).
The Cox proportional hazards regression model was used to estimate hazard ratios (HR) and corresponding 95% confidence intervals (CI) for the clinical outcomes of combined cardiovascular events (CVE), sudden death, MI, stroke, all-cause death and death due to infection. The first quartile of PAPP-A served as the reference group. PAPP-A was furthermore analyzed as a continuous variable. In the continuous analyses, the hazard ratios and 95% CI are given per standard deviation of PAPP-A concentrations.
All Cox regression analyses were adjusted for potential confounders including age, sex, smoking status, body mass index, atorvastatin treatment, systolic blood pressure, dialysis vintage, coronary artery disease, and levels of hemoglobin, HbA1c, albumin, phosphate, creatinine and total cholesterol in the multivariate analyses.
KaplaneMeier analyses were performed for the outcomes mentioned above. To compare the curves of the four groups, the log-rank test was computed.
Furthermore, we investigated PAPP-A in relation to conventional cardiovascular risk factors including age, sex, smoking status, systolic blood pressure, LDL-cholesterol and HbA1c status. We used Cox regression and ROC analyses to evaluate the models with a) conventional cardiovascular risk factors only and b) the addition of PAPP-A to conventional cardiovascular risk factors, respectively.
All p-values reported are two-sided and a p-value <0.05 was considered statistically significant. Analyses were performed using SPSS version 19.0.
Results
Patient characteristics and follow-up
Between March 1998 and October 2002, a total of 1255 Caucasian patients were included into the 4D study. The mean follow-up period was 3.96 years (median 4.0 years) on atorvastatin and 3.91 years (median 4.08 years) on placebo. A total of 1098 patients had a PAPP-A measurement at baseline. Of those, 534 patients died during follow-up, of whom 141 patients died of SCD and 114 due to infection. A total of 398 patients reached the CVE with MI and stroke occurring in 169 and 85 patients, respectively.
Mean age of the patients was 66 ± 8 years and median serum concentration of PAPP-A was 17.0 (IQR 13.4e20.9) mIU/L with minimum concentration of 6.4 mIU/L and maximum concentration of 124.7 mIU/L. Patients characteristics according to PAPP-A quartiles at baseline are shown in Table 1 .
Association of PAPP-A levels with adverse clinical outcomes
Baseline PAPP-A levels were significantly associated with allcause mortality and specific adverse clinical outcomes. We found no sex-specific differences when data were analyzed separately for men and for women. Detailed analysis of cardiovascular events revealed a significant association of high PAPP-A levels with sudden cardiac death but not with myocardial infarction. The respective HRs and corresponding 95% CI are shown in Table 2 (evaluation of PAPP-A as a continuous variable) and Table 3 (evaluation of PAPP-A according to quartiles). KaplaneMeier survival curves for overall mortality, combined cardiovascular events, mortality due to infection and sudden cardiac death are shown in Fig. 1 .
Cardiovascular events
Analysis of specific cardiovascular events revealed a significantly increased risk of sudden death in patients with high PAPP-A levels (adjusted HR 1.23, 95% CI 1.12e1.36, p ¼ 0.001 for PAPP-A as continuous variable (per standard deviation), adjusted HR 2.62, 95% CI 1.54e4.46, p < 0.001 for the 4 th vs. 1 st quartile). Similarly, patients with high PAPP-A levels had an increased risk of stroke in the quartile analyses (adjusted HR 2.80, 95% CI 1.30e6.00, p ¼ 0.008 for the 4 th vs. 1 st quartile). In contrast, no association of PAPP-A with myocardial infarction was found. Investigating cardiovascular events combined, patients in the 4 th quartile had the unequivocally worst prognosis (HR 1.46, 95% CI 1.06e2.01, p ¼ 0.022 vs. first quartile, adjusted analysis).
Mortality due to infection
Per standard deviation increase in PAPP-A level, patients had a 16% increased risk of infectious death after adjustment for potential 
All-cause mortality
Univariate Cox regression analyses revealed an 11% increase in all-cause death (HR 1.11, 95% CI 1.04e1.19, p < 0.001) per standard deviation increase in PAPP-A. This association persisted after adjustment for confounders (HR 1.14, 95% CI 1.06e1.23, p < 0.001, adjusted analysis). When PAPP-A was tested according to quartiles, patients in the 4 th quartile had an almost 2-fold increased risk as compared to the patients of the first quartile (adjusted HR 1.98, 95% CI 1.50e2.62, p < 0.001). Patients of the second and third PAPP-A quartile also had a significantly worse prognosis as compared to patients of the 1 st quartile.
Comparison of PAPP-A with conventional cardiovascular risk factors in the association with mortality
By Cox regression and ROC analyses, we investigated PAPP-A in relation to conventional cardiovascular risk factors including age, sex, smoking status, systolic blood pressure, LDL-cholesterol and HbA1c status ( Table 4 and Fig. 2) . The model including conventional cardiovascular risk factors only yielded an area under the ROC curve of 0.63 (95% CI 0.60e0.67). With addition of PAPP-A to the model, the area under the ROC curve increased to 0.66 (95% CI 0.63e0.69).
Discussion
Our study demonstrates a relationship of PAPP-A to the specific cardiovascular outcomes sudden cardiac death and stroke in patients with diabetes mellitus on maintenance hemodialysis. Our results, in a large patient population, furthermore prove PAPP-A to be useful as a prognostic marker for all-cause and infectious mortality in diabetic hemodialysis patients.
PAPP-A is produced by many cell types, both in reproductive and non-reproductive tissues. These cell types include fibroblasts, vascular smooth muscle cells, endothelial cells, osteoblasts and granulosa cells [17] . It is not synthesized in, but rather is bound and internalized by macrophages [18] . However, macrophages can contribute to PAPP-A overexpression due to production of proinflammatory cytokines IL-1 beta and TNF alpha [19] . By degrading of some, but not all IGFBPs, especially IGFBP-4 [3] , PAPP-A allows IGF-1 to bind to its receptors and so to exert its action. Some studies ascribe IGF-1 pro-atherosclerotic properties such as chemotaxis, LDL uptake and the release of proinflammatory cytokines by macrophages [20, 21] while others describe IGF-1 as an antiatherosclerotic molecule with anti-apoptotic, anti-inflammatory and antioxidant effects [22] . It was proposed that PAPP-A might be a cause of pathology but also a tool to increase IGF-1 and might increase as a reaction to IGF-1 decrease [23] . IGF-1 unlike PAPP-A was not an independent mortality predictor in hemodialysis patients [10] . PAPP-A plays a critical role in the development of atherosclerotic lesions as shown in animal models. PAPP-A knock out (KO) mice showed little or no lesion development; PAPP-A KO/ ApoE KO (ApoE KO representing a mouse model of atherosclerosis) fed with high fat diet had the same number of lesions compared to ApoE KO mice, but 60e80% reduction in aortic lesion area despite similar cholesterol and triglyceride levels [24] . Overexpression of PAPP-A (PAPP-A Tg, transgene) in arterial smooth muscle accelerated lesion progression in a mouse model of atherosclerosis [25] . On the other hand, PAPP-A is required for wound healing [26] , fracture repair [27] and PAPP-A deficient mice are resistant to neointimal formation after injury [28] . Further data suggest differential effects of chronic (transgenic) and transient (endogenous) PAPP-A expression on neointimal formation following vascular injury: PAPP-A Tg mice had 70e75% less neointima than wildtype mice 5e10 days after model injury [29] .
Our study describes the relationship of PAPP-A to mortality of diabetic patients with end-stage renal disease treated with hemodialysis. It demonstrates for the first time the association with specific cardiovascular events in a representative patient population. This association was addressed neither in a study with 261 long-term hemodialysis patients followed-up for 5 years [10] nor in the study by Etter et al. [9] with smaller number of deaths during the follow-up period (170 patients, 23 months).
Subanalysis of specific cardiovascular events pointed out the significance of PAPP-A for sudden death and stroke but not for myocardial infarction. PAPP-A might reflect the presence of unstable plaques and might also represent a marker that indicates an unfavorable state with high levels being at risk for sudden death. Diabetic patients on dialysis frequently die suddenly; sudden death accounts for one quarter e and therewith the highest proportionof deaths in these patients. Risk factors found so far included microand macrovascular disease, sympathetic overactivity, structural heart disease and electrolyte and volume shifts due to the hemodialysis procedure. However, these risk factors did not fully explain the excess risk of sudden death. PAPP-A may therefore be useful in risk assessment and monitoring, with patients of the highest quartile showing a more than 2.5 fold increased rate of sudden death as compared to those in the first quartile. Concerning stroke, we have previously demonstrated increased PAPP-A levels in patients with intracranial hemorrhage and in patients whose ischemic stroke was associated with coronary artery disease compared to healthy controls and to patients with isolated ischemic stroke [17] . In another study, PAPP-A expression was higher in both, vulnerable and ruptured carotid plaques and associated with activated macrophages as compared to stable plaques. Serum PAPP-A levels were also increased in these patients [30] . A recent study of 2568 patients presenting with chest pain demonstrated an independent association of higher levels of serum PAPP-A with short term risk of cardiovascular events (90 days) e myocardial (re)infarction, ischemic stroke and cardiovascularrelated death [13] . Mean serum levels of PAPP-A in that study were 24.6 ± 50.2 mIU/L (range 4.1e2154.4 mIU/L), the median was 14.0 mIU/L (interquartile range 9.3e25.2 mIU/L). The concentration of 34.6 mIU/L was set as the best prognostic cut-off (HR 5.28, 95% CI 3.81e7.31) [13] . Lack of any association of PAPP-A levels with myocardial infarction in our study was surprising, but could be explained in part by the discrepant nature of previous studies. Additionally, cardiovascular disease in end-stage renal disease patients differs from cardiovascular disease in the general population mainly due to a higher prevalence of calcifications and difference in atherosclerotic plaque stability. PAPP-A is also linked to mortality due to infection as demonstrated in this study as well as in our previous investigation [10] . PAPP-A expression in human atherosclerotic plaques is enhanced by proinflammatory cytokines [17, 19] ; association with some proinflammatory mediators in serum in patients with kidney diseases such as TNF alpha and IL-6 was also described [14] , while the relationship to C-reactive protein has not always been found [14, 10] . As such, it might reflect protein-energy wasting resulting in an instability of atherosclerotic plaques and worse prognosis of the patients. This can be supported by our finding that patients of the highest PAPP-A quartile had the lowest BMI, total cholesterol and triglyceride concentrations as indicators of protein-energy wasting. Peripheral vascular disease was the major cause of hospitalization (34%) during follow-up and the diabetic foot syndrome may have induced inflammation resulting in an increase in PAPP-A.
Tertti and coworkers observed an increase of PAPP-A after heparin administration [31] . That is why controversy about previous studies exists as heparin might have been administered in many patients before blood collection for PAPP-A analysis. PAPP-A was described as a marker for vulnerable plaques in patients with non-ST-segment elevation acute coronary syndrome and its increase was ascribed to the release from the vulnerable plaque [32] . In a subsequent publication Iversen et al. explained the increase by heparin administration and not due to excretion from vulnerable plaques [33] . However, H ajek et al. confirmed PAPP-A increases even in heparin naive patients with acute coronary syndromes [34] . For measurement of basal values, in this study as well as in our previous investigations, blood was taken before heparin administration to avoid its influence. However, it still remains questionable whether repeated heparin administration during each hemodialysis as well as repeated intravenous iron administration [35] could also contribute to slight chronic PAPP-A increases apart from loss of kidney function and a proinflammatory state.
Methodology used for PAPP-A determination is another point that has to be addressed. PAPP-A exists in a complexed form representing the predominant form in pregnancy [36] . It also exists in a free form, which is most likely the only relevant form in acute coronary syndromes [37] . In hemodialysis patients, both total and free PAPP-A are increased [31] . The assay used in this study detected both forms. As in our previous studies, using the same assay, we disclosed increases during hemodialysis after heparin administration [38, 39] . This increase should be caused by an increase of free PAPP-A [31] . PAPP-A is cleared rapidly, the majority with a half-life of 13 min [40] . Usefulness of this assay was demonstrated even in predicting cardiovascular events in 2568 patients with cardiac chest pain [13] .
Potential limitations of our study need to be acknowledged. PAPP-A concentrations measured in this study were lower than in previous studies [9, 10] although the same method was used for PAPP-A determination. Patients in this study had round 30% reduced median and quartile PAPP-A levels but also lower serum creatinine level than in a previous one [10] and we cannot exclude potential effect of different long-term dialysis treatment and medication on PAPP-A levels. Samples were stored at À80 C for more than ten years until analysis and the effect of such a long time of storage on PAPP-A levels has not yet been tested. However, despite lower values in the whole study our findings are in line with previous studies showing a worse prognosis of hemodialysis patients with higher PAPP-A levels, especially in the highest quartile.
In conclusion, our study shows a significant role of PAPP-A for cardiovascular events, specifically for sudden death and stroke, in patients with diabetes on dialysis. Together with the association with mortality due to infection PAPP-A might reflect a general unfavorable status and fit into the concept of progressive atherosclerotic disease. PAPP-A may be useful for risk assessment and monitoring in diabetic hemodialysis patients.
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